Skip to main content
Figure 5 | Molecular Cancer

Figure 5

From: HMGN2, a new anti-tumor effector molecule of CD8+ T cells

Figure 5

T-Ag activated T cells and induced HMGN2 expression in activated T cell populations. PBMCs were seeded at a density of 1 × 107 per well in 6 well plates and stimulated with 150 μg/ml T-Ag for 7 days. Normal medium was used as the control. Cells were removed and (A) stained with CD44-APC/CD8-PE/intracellular HMGN2-2nd-Ab-FITC. (Aa) Gate 1 (CD44high) as the activated T cells, gate R6 (CD44low) as the naïve T cells. (Ab-Ac) Intracellularly expression of HMGN2 in CD44high activated CD8+ T cells (Ab) and CD44low naïve CD8+ T cells (Ac). (B) Error bars represented the percentage of activation PBMCs after stimulated with T-Ag. (C) Error bars represented HMGN2 intracellular expression positive rate (%) in T-Ag-activated CD8+T cell populations. Data are represented as means ± SD of three independent experiments. *Significantly higher compared to medium control (p < 0.05). #Significantly higher compared to CD44lowCD8+ naïve T cells (p < 0.05).

Back to article page